47-year-old BethAnn Telford will run 7 marathons on 7 continents in 7 days. In 2005, she was diagnosed with brain cancer.
Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about the convenience and safety of subcutaneous delivery of daratumumab in multiple myeloma patients.
Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about very impressive data showing the efficacy of daratumumab, lenalidomide, and dexamethasone to treat relapsed or refractory multiple myeloma patients.
The FDA issued a warning for cancer patients to not use of the drug PNC-27 which is a non-approved cancer treatment sold online, mostly in other countries.
At UFC 207, new UFC Bantamweight Champion Cody Garbrandt shares his belt with his inspirational coach – 10-year-old Maddux Maple who is a cancer survivor.
A total of 37 orphan drugs were given approval by the FDA for various rare disease indications. Much lower than last year’s record breaking 48 approvals.
Dr Badie said, “I believe these recent results show we have a potential breakthrough treatment that may have a remarkable impact on patients with malignant brain tumors.”
The developer of the drug—Seattle Genetics—stated that 6 patients have been identified with hepatotoxicity and 4 of them have died.
The FDA has approved the orphan drug Rubraca (rucaparib) to treat women with advanced ovarian cancer who have been treated with 2 or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test.
At 17.5 months of follow-up, the overall response was significantly higher for brentuximab vedotin than for physician’s choice of therapy: 56% vs 13%, respectively (P < .0001). Median progression-free survival was also significantly higher in the brentuximab-treated group: 16.7 months vs 3.5 months (P < .0001).